BridgeMD
The headache-inducing effects of cilostazol in men and women with migraine without aura
EU CTIS ID: 2025-521520-29-00
What this study is testing
The main objective of this study is to investigate the role of the intracellular messenger cAMP in migraine by exploring potential sex-related differences in the response to cilostazol in individuals with migraine.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Healthy men and women with a diagnosis of episodic migraine without aura according to the International Classification
- Age: 18-65 years
- Weight: 50-100 kg
- Safe contraception (including hormonal therapies, intrauterine devices and/or oral pills) for women during the entire period of the study
- Fluency in Danish or English
You likely can't join if
- Any other type of headache (excluding < 3 days of tension-type headache per month), according to the International Classification
- History or clinical signs of cardiovascular disease, cardiac arrhythmia, unstable angina pectoris, impaired liver function and/or kidney function
- Recent history of myocardial infarction or major cardiac surgery
- Anamnestic or clinical signs of mental illness, abuse or smoking
- Anamnestic or clinical signs of diseases of any kind considered by the investigating physician relevant for participation in the study
- Use of concomitant medications that have changed in dosage within 14 days prior to screening or are expected to change during the study period
See the full eligibility criteria
- Healthy men and women with a diagnosis of episodic migraine without aura according to the International Classification
- Age: 18-65 years
- Weight: 50-100 kg
- Safe contraception (including hormonal therapies, intrauterine devices and/or oral pills) for women during the entire period of the study
- Fluency in Danish or English
- Any other type of headache (excluding < 3 days of tension-type headache per month), according to the International Classification
- History or clinical signs of cardiovascular disease, cardiac arrhythmia, unstable angina pectoris, impaired liver function and/or kidney function
- Recent history of myocardial infarction or major cardiac surgery
- Anamnestic or clinical signs of mental illness, abuse or smoking
- Anamnestic or clinical signs of diseases of any kind considered by the investigating physician relevant for participation in the study
- Use of concomitant medications that have changed in dosage within 14 days prior to screening or are expected to change during the study period
- Concomitant use of anticoagulants, antiaggregants and drugs that inhibit CYP3A4 and CYP2C19 activity
- Positive pregnancy test at the Screening and/or before the start of the experiment
- Known allergy to any component of cilostazol “Aliud”
- Member of investigational site staff or relative of investigators
- Headache less than 24 hours before the start of the experiment
- Drinking coffee, cola or alcohol less than 8 hours before the start of the experiment
- Assumption of analgesic medications in the 24 hours preceding the experimental days
- Hypertension (> 150/100 mmHg) or hypotension (< 90/50 mmHg) at the Screening Visit
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.